Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer
Journal of Clinical Oncology2020Vol. 38(15), pp. 1676–1684
Citations Over TimeTop 10% of 2020 papers
Vladimir Avkshtol, Karen Ruth, Eric A. Ross, M.A. Hallman, Richard E. Greenberg, R Price, Brooke K. Leachman, Robert G. Uzzo, Charlie Ma, David Chen, Daniel M. Geynisman, Mark L. Sobczak, Eddie Zhang, J.K. Wong, Alan Pollack, Eric M. Horwitz
Abstract
H-IMRT failed to demonstrate superiority compared with C-IMRT in long-term disease outcomes.
Related Papers
- → How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk(2021)42 cited
- → Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer(2011)9 cited
- → Androgen deprivation therapy for prostate cancer(2017)4 cited
- → Uncovering the Metabolic Complications of Androgen Deprivation Therapy in Patients with Prostate Cancer—Where Do We Take it Next?(2015)2 cited
- Complications of androgen deprivation therapy in prostate cancer / a review(2017)